<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35524784</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1084</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>European radiology</Title>
          <ISOAbbreviation>Eur Radiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Background parenchymal enhancement in contrast-enhanced MR imaging suggests systemic effects of intrauterine contraceptive devices.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00330-022-08809-0</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Levonorgestrel-releasing intrauterine contraceptive devices (LNG-IUDs) are designed to exhibit only local hormonal effects. There is an ongoing debate on whether LNG-IUDs can have side effects similar to systemic hormonal medication. Benign background parenchymal enhancement (BPE) in dynamic contrast-enhanced (DCE) MRI has been established as a sensitive marker of hormonal stimulation of the breast. We investigated the association between LNG-IUD use and BPE in breast MRI to further explore possible systemic effects of LNG-IUDs.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Our hospital database was searched to identify premenopausal women without personal history of breast cancer, oophorectomy, and hormone replacement or antihormone therapy, who had undergone standardized DCE breast MRI at least twice, once with and without an LNG-IUD in place. To avoid confounding aging-related effects on BPE, half of included women had their first MRI without, the other half with, LNG-IUD in place. Degree of BPE was analyzed according to the ACR categories. Wilcoxon-matched-pairs signed-rank test was used to compare the distribution of ACR categories with vs. without LNG-IUD.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-eight women (mean age, 46 years) were included. In 24/48 women (50% [95% CI: 35.9-64.1%]), ACR categories did not change with vs. without LNG-IUDs. In 23/48 women (48% [33.9-62.1%]), the ACR category was higher with vs. without LNG-IUDs; in 1/48 (2% [0-6%]), the ACR category was lower with vs. without LNG-IUDs. The change of ACR category depending on the presence or absence of an LNG-IUD proved highly significant (p &lt; 0.001).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of an LNG-IUD can be associated with increased BPE in breast MRI, providing further evidence that LNG-IUDs do have systemic effects.</AbstractText>
          <AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">• The use of levonorgestrel-releasing intrauterine contraceptive devices is associated with increased background parenchymal enhancement in breast MRI. • This suggests that hormonal effects of these devices are not only confined to the uterine cavity, but may be systemic. • Potential systemic effects of levonorgestrel-releasing intrauterine contraceptive devices should therefore be considered.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huck</LastName>
            <ForeName>Luisa Charlotte</ForeName>
            <Initials>LC</Initials>
            <Identifier Source="ORCID">0000-0002-4898-4294</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic and Interventional Radiology, University of Aachen, RWTH, Pauwelsstr. 30, 52074, Aachen, Germany. lhuck@ukaachen.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Truhn</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic and Interventional Radiology, University of Aachen, RWTH, Pauwelsstr. 30, 52074, Aachen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilpert</LastName>
            <ForeName>Caroline</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic and Interventional Radiology, University of Aachen, RWTH, Pauwelsstr. 30, 52074, Aachen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zanderigo</LastName>
            <ForeName>Eloisa</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic and Interventional Radiology, University of Aachen, RWTH, Pauwelsstr. 30, 52074, Aachen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raaff</LastName>
            <ForeName>Vanessa</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic and Interventional Radiology, University of Aachen, RWTH, Pauwelsstr. 30, 52074, Aachen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dethlefsen</LastName>
            <ForeName>Ebba</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic and Interventional Radiology, University of Aachen, RWTH, Pauwelsstr. 30, 52074, Aachen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bode</LastName>
            <ForeName>Maike</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic and Interventional Radiology, University of Aachen, RWTH, Pauwelsstr. 30, 52074, Aachen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuhl</LastName>
            <ForeName>Christiane Katharina</ForeName>
            <Initials>CK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic and Interventional Radiology, University of Aachen, RWTH, Pauwelsstr. 30, 52074, Aachen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Eur Radiol</MedlineTA>
        <NlmUniqueID>9114774</NlmUniqueID>
        <ISSNLinking>0938-7994</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Background parenchymal enhancement</Keyword>
        <Keyword MajorTopicYN="N">Breast MRI</Keyword>
        <Keyword MajorTopicYN="N">Contraception</Keyword>
        <Keyword MajorTopicYN="N">Levonorgestrel</Keyword>
        <Keyword MajorTopicYN="N">Levonorgestrel-releasing intrauterine device</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>11</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35524784</ArticleId>
        <ArticleId IdType="doi">10.1007/s00330-022-08809-0</ArticleId>
        <ArticleId IdType="pii">10.1007/s00330-022-08809-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Nelson AL, Massoudi N (2016) New developments in intrauterine device use: focus on the US. Open Access J Contracept 7:127</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OAJC.S85755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finer LB, Zolna MR (2016) Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med 374:843–852</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMsa1506575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danvers AA, Stuart GS, Bryant AG (2014) Lawsuits against Mirena®: potential impact on public health. Contraception 89:489–492</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.contraception.2014.03.013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC, reproductive health, contraception, birth control methods. Available via https://www.cdc.gov/reproductivehealth/contraception/index.htm On March 15, 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Conz L, Mota BS, Bahamondes L et al (2020) Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 99:970–982. https://doi.org/10.1111/aogs.13817</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/aogs.13817</ArticleId>
            <ArticleId IdType="pubmed">31990981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø (2016) Association of hormonal contraception with depression. JAMA Psychiatry 73:1154–1162</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapsychiatry.2016.2387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aleknaviciute J, Tulen JHM, De Rijke YB et al (2017) The levonorgestrel-releasing intrauterine device potentiates stress reactivity. Psychoneuroendocrinology 80:39–45. https://doi.org/10.1016/j.psyneuen.2017.02.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psyneuen.2017.02.025</ArticleId>
            <ArticleId IdType="pubmed">28315609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slattery J, Morales D, Pinheiro L, Kurz X (2018) Cohort study of psychiatric adverse events following exposure to levonorgestrel-containing intrauterine devices in UK general practice. Drug Safety 41:951–958</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40264-018-0683-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Depypere HT, Stanczyk FZ, Croubels S et al (2019) Breast levonorgestrel concentrations in women using a levonorgestrel-releasing intrauterine system. Contraception 100:299–301. https://doi.org/10.1016/j.contraception.2019.07.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.contraception.2019.07.002</ArticleId>
            <ArticleId IdType="pubmed">31302122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gossner J (2013) Marked increase of breast density due to a levonorgestrel-releasing intrauterine device. JBR-BTR 96:396. https://doi.org/10.5334/jbr-btr.529</Citation>
        </Reference>
        <Reference>
          <Citation>King V, Gu Y, Kaplan JB et al (2012) Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol 22:2641–2647</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00330-012-2553-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brooks JD, Sung JS, Pike MC et al (2018) MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women. Int J Cancer 143:823–830</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.31370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen NL, Kuhl CK, Barabasch A, Strobel K, Schrading S (2014) Does MRI breast “density” (degree of background enhancement) correlate with mammographic breast density? J Magn Reson Imaging 40:483–489</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmri.24495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller-Schimpfle M, Ohmenhaüser K, Stoll P, Dietz K, Claussen CD (1997) Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 203:145–149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiology.203.1.9122383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kajihara M, Goto M, Hirayama Y et al (2013) Effect of the menstrual cycle on background parenchymal enhancement in breast MR imaging. Magn Reson Med Sci:2012–0022</Citation>
        </Reference>
        <Reference>
          <Citation>Preibsch H, Wanner L, Bahrs SD et al (2016) Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Eur Radiol 26:1590–1596. https://doi.org/10.1007/s00330-015-4011-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00330-015-4011-x</ArticleId>
            <ArticleId IdType="pubmed">26382845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YJ, Kim SH, Choi BG et al (2014) Impact of radiotherapy on background parenchymal enhancement in breast magnetic resonance imaging. Asian Pac J Cancer Prev 15:2939–2943</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/APJCP.2014.15.7.2939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King V, Goldfarb SB, Brooks JD et al (2012) Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. Radiology 264:670–678</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.12112669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King V, Kaplan J, Pike MC et al (2012) Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 18:527–534</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/tbj.12002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schrading S, Schild H, Kühr M, Kuhl C (2014) Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study. Radiology 271:45–55. https://doi.org/10.1148/radiol.13131198</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.13131198</ArticleId>
            <ArticleId IdType="pubmed">24475835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King V, Brooks JD, Bernstein JL et al (2011) Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 260:50–60</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.11102156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray KM, Kerlikowske K, Lobach IV et al (2018) Effect of background parenchymal enhancement on breast MR imaging interpretive performance in community-based practices. Radiology 286:822–829</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.2017170811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arasu VA, Miglioretti DL, Sprague BL et al (2019) Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk. J Clin Oncol 37:954</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.18.00378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dontchos BN, Rahbar H, Partridge SC et al (2015) Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on MR images, and mammographic density associated with breast cancer risk? Radiology 276:371–380</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.2015142304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhl CK, Strobel K, Bieling H et al (2017) Supplemental breast MR imaging screening of women with average risk of breast cancer. Radiology 283:361–370</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.2016161444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhl CK, Bieling HB, Gieseke J et al (1997) Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 203:137–144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiology.203.1.9122382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung JS, Corben AD, Brooks JD et al (2018) Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI. Breast Cancer Res Treat 172:487–496. https://doi.org/10.1007/s10549-018-4916-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-018-4916-6</ArticleId>
            <ArticleId IdType="pubmed">30140962</ArticleId>
            <ArticleId IdType="pmc">6697118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao GJ, Henze Bancroft LC, Strigel RM et al (2020) Background parenchymal enhancement on breast MRI: a comprehensive review. J Magn Reson Imaging 51:43–61. https://doi.org/10.1002/jmri.26762</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmri.26762</ArticleId>
            <ArticleId IdType="pubmed">31004391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe JN (1976) Breast parenchymal patterns and their changes with age. Radiology 121:545–552</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/121.3.545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potten CS, Watson R, Williams G et al (1988) The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58:163–170</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.1988.185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delille J-P, Slanetz PJ, Yeh ED et al (2005) Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging—initial observations. Radiology 235:36–41</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.2351040012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dehlendorf C, Tharayil M, Anderson N et al (2014) Counseling about IUDs: a mixed-methods analysis. Perspect Sex Reprod Health 46:133–140</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1363/46e0814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beatty MN, Blumenthal PD (2009) The levonorgestrel-releasing intrauterine system: safety, efficacy, and patient acceptability. Ther Clin Risk Manag 5:561</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19707273</ArticleId>
            <ArticleId IdType="pmc">2724187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang SS, Ko EY, Han BK et al (2014) Background parenchymal enhancement on breast MRI: influence of menstrual cycle and breast composition. J Magn Reson Imaging 39:526–534. https://doi.org/10.1002/jmri.24185</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmri.24185</ArticleId>
            <ArticleId IdType="pubmed">23633296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sergison JE, Maldonado LY, Gao X, Hubacher D (2019) Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis. Am J Obstet Gynecol 220:440-448.e448. https://doi.org/10.1016/j.ajog.2018.12.008</Citation>
        </Reference>
        <Reference>
          <Citation>Dontchos BN, Rahbar H, Partridge SC, Lehman CD, DeMartini WB (2019) Influence of menstrual cycle timing on screening breast MRI background parenchymal enhancement and diagnostic performance in premenopausal women. J Breast Imaging 1:205–211. https://doi.org/10.1093/jbi/wbz022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jbi/wbz022</ArticleId>
            <ArticleId IdType="pubmed">31538142</ArticleId>
            <ArticleId IdType="pmc">6735589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CH, Bryce Y, Zheng J et al (2020) Outcome of screening MRI in premenopausal women as a function of the week of the menstrual cycle. AJR Am J Roentgenol 214:1175–1181. https://doi.org/10.2214/ajr.18.19960</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/ajr.18.19960</ArticleId>
            <ArticleId IdType="pubmed">32160053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfleiderer SO, Sachse S, Sauner D et al (2004) Changes in magnetic resonance mammography due to hormone replacement therapy. Breast Cancer Res 6:R232–R238. https://doi.org/10.1186/bcr779</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr779</ArticleId>
            <ArticleId IdType="pubmed">15084246</ArticleId>
            <ArticleId IdType="pmc">400676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heller SL, Young Lin LL, Melsaether AN, Moy L, Gao Y (2018) Hormonal effects on breast density, fibroglandular tissue, and background parenchymal enhancement. Radiographics 38:983–996. https://doi.org/10.1148/rg.2018180035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/rg.2018180035</ArticleId>
            <ArticleId IdType="pubmed">29856684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giess CS, Yeh ED, Raza S, Birdwell RL (2014) Background parenchymal enhancement at breast MR imaging: normal patterns, diagnostic challenges, and potential for false-positive and false-negative interpretation. Radiographics 34:234–247</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/rg.341135034</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
